Check for updates
TJ ISSN 0300-8916
ORIGINAL RESEARCH ARTICLE
Open Access
Peritoneal metastases from adrenal cortical carcinoma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Paul H. Sugarbaker
Program in Peritoneal Surface Oncology, Center for Gastrointestinal Malignancy, MedStar Washington Hospital Center, Washington, DC - USA
ABSTRACT
Purpose: Adrenal cortical carcinoma is a rare cancer that often presents in an advanced stage. Not only systemic metastases but also local recurrence and peritoneal metastases prevent long-term survival in these patients. Methods: A profoundly symptomatic patient with extensive peritoneal metastases and local recurrence was treated using cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with melpha- lan as the chemotherapy agent.
Results: Relative sparing of the small bowel within the abdomen and pelvis allowed a visible complete resection of all cancer. The HIPEC with melphalan was used to control microscopic residual disease. Similar surgical technol- ogy used in this patient could be used to prevent local recurrence and peritoneal metastases in patients at the time of resection of the primary adrenal cortical carcinoma.
Conclusions: Rare diseases may have peritoneal metastases as a component of disease progression and profit from treatment with CRS plus HIPEC. The clinical features suggesting a favorable outcome from this combined treatment are relative sparing of small bowel and its mesentery, absence of disease outside the abdomen, low- grade disease, or limited extent of high-grade disease.
Keywords: Adrenal cortical carcinoma, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Hyperthermic intraperitoneal chemotherapy, Melphalan, Peritoneal metastases
Introduction
Initial success with the potentially curative treatment of peritoneal metastases occurred with low-grade appendiceal mucinous neoplasms causing the pseudomyxoma peritonei syndrome (1). Cytoreductive surgery (CRS) plus perioperative intraperitoneal chemotherapy is now the global standard of care for this rare disease (2). This management plan has been used to treat peritoneal metastases from more common ma- lignancies with peritoneal dissemination such as colorectal cancer, gastric cancer, and ovarian cancer (3-5). However, rare abdominal and pelvic malignancies that produce peritoneal metastases have been successfully treated using this manage- ment strategy (6). Adrenal cortical carcinoma is one of these rare cancers that progress with local recurrence and peritoneal metastases in approximately 50% of patients (7). In this report,
we describe the management of a patient with a large extent of local recurrence plus peritoneal metastases of adrenal cor- tical carcinoma. Complete CRS plus hyperthermic intraperito- neal melphalan was used to produce a short-term favorable outcome. A literature review of other unusual diseases treat- ed by CRS plus hyperthermic intraperitoneal chemotherapy (HIPEC) follows. Our goal is to define the selection criteria for patients with peritoneal metastases from rare diseases for this comprehensive treatment strategy.
Patient presentation
In December 2015, a 31-year-old woman presented with abdominal pain from progressive peritoneal metastases from metastatic adrenal cortical carcinoma. Her medical history re- vealed back pain beginning in September 2013. In March 2014, the pain suddenly increased and abdominal distention was first noted. Computed tomography (CT) showed a large right-sided hepatic malignancy thought to be a hepatocellular carcinoma. On April 9, 2014, a right hepatectomy and right adrenalectomy were performed. Pathology showed an unexpected adrenal cortical carcinoma with extensive invasion into the right liver. Postoperative radiation to the adrenal resection site was per- formed. From September 2014 through February 2015, the patient received systemic chemotherapy. In May 2015, an open and close surgical procedure was performed and the
Accepted: September 1, 2016 Published online: September 27, 2016
Corresponding author:
Paul H. Sugarbaker, MD, FACS, FRCS MedStar Washington Hospital Center 106 Irving St., NW, Suite 3900 20010 Washington, DC, USA Paul.Sugarbaker@medstar.net
Slice 1
SCOTTSDALE MEDICAL IMAGING LTD
Slice 2
A
AX ABD VENOUS, 12/08/2015
AX ABD VENOUS, 12/06/2015 Fr; 27, WL: 50, WW. 450
SCOTTSDALE MEDICAL IMAGING LTD
Fi: 14, WL: 50, WW. 450
SIEMENS Biograph 16
SIEMENS Biograph 16
#
L
#
L
120
mA:
3 mm
500 mm
DFOV: 346 mm
3 mm
12: 0
500 mm DFOV: 346 mm
Slice 3 AX ABD VENOUS, 12/08/2015
A
SCOTTSDALE MEDICAL IMAGING LTD
Slice 4
A
Fr: 53, WL: 50, WW. 450
SIEMENS Biograph 16
AX ABD VENOUS, 12/08/2015 Fr: 81, WL: 50, WW. 450
SCOTTSDALE MEDICAL IMAGING LTD
SIEMENS Biograph 16
#
L
#
L
120
120
3 mm
500 m
DFOV: 345 mm
3 mm
500 mm
a: 0
Ta: 0
OFOV: 345 mm
Slice 5
A
Slice 6
A
AX ABDI VENOUS, 12/08/2015
SCOTTSDALE MEDICAL IMAGING LTD
AX ABD VENOUS, 12/08/2015 Fi 123, WL: 50, WW: 450
SCOTTSDALE MEDICAL IMAGING LTD
Fi: 104, WL: SO, WW: 450
SIEMENS Biograph 16
SIEMENS Biograph 16
L
R
120
NC 120
mA
mA
3 mm
500 mm
3 mm
500 mm
12: 0
DFOV: 345 mm
12: 0
OFOV: 345 mm
widespread peritoneal metastases were considerably unresect- able. On July 7, 2015, a debulking procedure to remove the greater omentum was performed and hyperthermic intraperi- toneal cisplatin was used. This palliative procedure resulted in approximately 5 months of benefit.
Computed tomography on December 8, 2015, showed a 6-cm pleural mass medially and inferiorly in the right thorax.
More than half of the right kidney was destroyed by the mass. Small bowel was not dilated. It was compartmentalized in the right mid and lower abdomen by large cancerous masses. Below the umbilicus, no small bowel was visible on CT, but the colon and rectum were not dilated. Tumor masses sur- rounded the bladder but there was no ureteral obstruction (see Fig. 1, CT slices 1-6).
W
On December 30, 2015, the patient underwent a 13-hour cytoreduction that included a right nephrectomy and partial resection of the right hemidiaphragm and pleural mass, hys- terectomy and bilateral salpingo-oophorectomy, pelvic peri- tonectomy, and left colectomy with low anastomosis (Fig. 2). Hyperthermic intraperitoneal chemotherapy with melphalan at 60 mg/m2, 42℃ for 60 minutes was used prior to intesti- nal anastomosis and abdominal closure (8). The patient spent 14 days in the surgical intensive care unit and was discharged after a 31-day hospitalization.
Computed tomography performed on April 23, 2016, showed a new mass lesion in the left adrenal gland. Mag- netic resonance imaging on June 3, 2016, confirmed that the mass had rapidly expanded to 9.8 5.0 6.7 cm. With a preop- erative diagnosis of second primary adrenal cortical carci- noma, the patient underwent exploratory laparotomy and left adrenalectomy on June 29, 2016. There was no evidence of peritoneal metastases and there was an R0 resection of the left adrenal cortical carcinoma with adjuvant melphalan at 50 mg/m2 at 42℃ for 60 minutes. She was discharged on postoperative day 5. Her current performance status is 0 and she is clinically disease-free.
Discussion
Adrenocortical carcinoma has not been previously iden- tified as a malignancy appropriate for treatment by CRS plus HIPEC. Elias (9), in a personal communication, described 4 patients, 3 of whom had died, and concluded that com- plete cytoreduction may be of benefit in selected cases but that HIPEC is unlikely to be of benefit because of chemo- therapy resistance of the tumor. Hughes et al have generat- ed a protocol for treatment of peritoneal metastases from adrenocortical carcinoma but as yet no publications have been forthcoming (10). Our patient had a complete resec- tion of a very large volume of disease followed by HIPEC
with melphalan. Her short-term outcome (palliation) has been excellent as a result of the complete visible removal of abdominal and pelvic cancer. Longer follow-up is neces- sary before any conclusions concerning maintenance of the complete cytoreduction by melphalan can occur.
The natural history of adrenocortical carcinoma suggests that surgical technology to improve local control of the pri- mary malignancy may result in improved outcomes with this disease process. In 2010, Leboulleux et al (11) reported a 27% incidence of peritoneal metastases in 58 patients treat- ed by open surgery. In 6 patients resected by laparoscopic surgery, the incidence of peritoneal metastases was 67%. In 2012, Miller et al (12) reported on 110 open resections with a 16% incidence of peritoneal metastases. In 56 lapa- roscopic resections, the incidence of peritoneal metastases was 30%. Likewise, in 2012, Lombardi et al (13) published a multi-institutional study of 126 open resections with a 19% incidence of peritoneal metastases. Thirty laparoscopic re- sections were reported with a 21% incidence of peritoneal metastases.
In 2016, Amini et al (7) gathered information on 180 patients from 13 institutions who had a potentially cura- tive resection of adrenocortical carcinoma. Two-thirds of the patients experienced disease recurrence. This was local only in 36.3%, distant only in 45.1%, and combined local- regional and distant in 18.6%. Increasing T-stage was associ- ated with local-regional recurrence (p = 0.02). Margonis et al (14) reported that the surgical margin status had an impact on long-term outcomes. An R0 resection was achieved in 126 patients (76.4%) and R1 resection in 39 (23.6%). Median and 5-year overall survival for patients undergoing R0 resec- tion were 96.3 months and 64.8% as compared to 25.1 months and 33.8% for patients having an R1 resection (p<0.001). The authors concluded that an emphasis on surgical technique to achieve an R0 margin of resection was crucial to optimizing long-term survival.
The high incidence of local-regional recurrence and peritoneal metastases in adrenocortical carcinoma patients suggests that additional surgical technology is required to optimize the primary resection of these patients. Local- regional failure including peritoneal metastases was report- ed to be 16% to 67% depending on the institution and the method of resection (open vs laparoscopic). No reports that describe treatments or results of treatment for local-region- al or metastatic disease were available. This report of CRS plus hyperthermic intraperitoneal melphalan as a possible approach to peritoneal metastases from this disease is the first in the literature.
Adrenal cortical carcinoma is one of many rare diseases that cause peritoneal metastases. Many of these rare diseas- es manifest peritoneal metastases that have been success- fully treated by CRS and HIPEC (6). Urachal adenocarcinoma with peritoneal metastases, ovarian teratoma with peritoneal metastases, and small bowel adenocarcinoma with peritone- al metastases are a few with accompanying literature. Table I lists a large number of rare diseases that have had treatment with CRS and HIPEC.
An important consideration of this new concept in man- agement of peritoneal metastases from rare diseases is the selection process. The surgeon wishes to perform CRS and
TABLE I - Rare diseases having isolated peritoneal metastases and possibly treated by cytoreductive surgery and hyperther- mic intraperitoneal chemotherapy
Abdominal/pelvic sarcoma
Neuroendocrine tumors
Urachal adenocarcinoma Low malignant potential ovarian tumors Colonic polyps (traumatic resection)
Mesenteric cysts
Pararectal hamartoma
Adrenocortical adenocarcinoma
Desmoplastic small round cell tumor
Endocervical mucinous adenocarcinoma
Endometrial adenocarcinoma
Hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma
Germ cell testicular tumor
Frantz pseudopapillary tumor of the pancreas
Nephroblastoma
Cylindroma
Adenocarcinoma of unknown primary site (normal appendix identified)
TABLE II - Clinical features suggesting a favorable outcome for use of cytoreductive surgery and hyperthermic intraperito- neal chemotherapy in patients with peritoneal metasta- ses from rare diseases and clinical features suggesting cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be recommended
Clinical features suggesting a favorable outcome
1. General medical condition compatible with survival and recov- ery from the procedure.
2. Clinical information regarding the peritoneal metastases com- patible with a complete or near complete cytoreduction.
a. Relative sparing of the small bowel and colon.
b. Absence of disease outside the abdomen/pelvis.
c. If hepatic metastases are present, they are limited, compat- ible with wedge resection.
d. Absence of disease within the porta hepatis.
3. With a high-grade malignancy, a low or moderate peritoneal cancer index.
4. Symptomatic patient.
Clinical features suggesting an unfavorable outcome
1. Poor performance status.
2. Rapid progression of a high-grade disease process.
3. Low likelihood of a response to perioperative chemotherapy.
4. Prior abdominal or pelvic radiation therapy.
5. Asymptomatic from peritoneal metastases.
HIPEC on those patients who are likely to profit and who have an acceptable morbidity and mortality that accompa- nies these treatments. All or almost all diseases within the abdomen and pelvis must be removed by peritonectomy procedures and visceral resections (1, 6). The radiologic evaluation should show a relative sparing of small bowel and small bowel mesentery of metastatic disease. Also, there should be no metastases in the lungs or distant lymph nodes. If hepatic metastases are present, they should be of limited extent and resectable without major parenchymal liver resection. High-grade disease intimately associated with the porta hepatis is rarely resectable (15, 16). If the malignancy is aggressive, only a small or moderate perito- neal cancer index may be present (17). The top portion of Table II lists the clinical features suggesting a favorable out- come. The lower portion of Table II lists the clinical features that suggest that CRS plus HIPEC may not be indicated (18, 19). Patients with a poor performance status or rapidly pro- gressing high-grade disease will not profit (18). The disease is not likely to show a chemotherapy response to HIPEC if extensive prior treatment with chemotherapy had occurred. Prior radiation therapy makes an extensive surgery more dangerous (19).
Disclosures
Financial support: No financial support was received for this sub- mission.
Conflict of interest: None of the authors has conflict of interest with this submission.
References
1. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727-731.
2. Sugarbaker PH. New standard of care for appendiceal epitheli- al neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69-76.
3. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with periopera- tive intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24(24):4011-4019.
4. Coccolini F, Catena F, Glehen O, et al. Complete versus incom- plete cytoreduction in peritoneal carcinosis from gastric can- cer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(7):911-919.
5. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cy- toreductive surgery and heated intraoperative intraperito- neal chemotherapy for treatment of peritoneal carcinoma- tosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18(12):1943-1950.
6. Sugarbaker PH. Management of unusual abdominal and pel- vic neoplasms with peritoneal dissemination: Case reports and literature review. (In) Sugarbaker PH (Ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. Cine-Med Publishing: Woodbury, CT, 2012, pp. 137-158.
7. Amini N, Margonis GA, Kim Y, et al. Curative resection of ad- renocortical carcinoma: Rates and patterns of postoperative recurrence. Ann Surg Oncol. 2016;23(1):126-133.
8. Bijelic L, Sugarbaker PH, Stuart OA. Hyperthermic intraperi- toneal chemotherapy with melphalan: A summary of clinical
and pharmacologic data in 34 patients. Gastroenterol Res Pract Volume 2012; 2012: Article ID 827534, 5 pages
9. Elias D. Personal communication, Amsterdam, 2014.
10. Surgery and Heated Chemotherapy for Adrenocortical Carci- noma. Sponsor: National Cancer Institute (NCI). ClinicalTrials. gov Identifier: NCT01833832
11. Leboulleux S, Deandreis D, Al Ghuzlan A, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010;162(6):1147-1153.
12. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152(6):1150-1157.
13. Lombardi CP, Raffaelli M, De Crea C, et al. Open versus endo- scopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery. 2012;152(6):1158-1164.
14. Margonis GA, Kim Y, Prescott JD, et al. Adrenocortical carcino- ma: Impact of surgical margin status on long-term outcomes. Ann Surg Oncol. 2016;23(1):134-141.
15. Sugarbaker PH. Preoperative assessment of cancer patients with peritoneal metastases for complete cytoreduction. Indian J Surg Oncol. 2016; 10.1007/s13193-016-0518-0.
16. Rivard JD, Temple WJ, McConnell YJ, Sultan H, Mack LA. Pre- operative computed tomography does not predict resectability in peritoneal carcinomatosis. Am J Surg. 2014;207(5):760-764, discussion 764-765.
17. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15(1):49-58.
18. Pelz JOW, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in pa- tients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9-15.
19. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Pre- dicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004; 91(6):739-746.